Accession Number: | 0001209191-22-026087 |
Date: | 2022-04-26 |
Issuer: | ATYR PHARMA INC (LIFE) |
Original Submission Date: |
COUGHLIN TIMOTHY
C/O ATYR PHARMA, INC.
3545 JOHN HOPKINS COURT SUITE 250
SAN DIEGO, CA 92121
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
RESTRICTED STOCK UNITS | 0.0 | 2022-04-26 | deemed execution date | A | 6,000 (a) | common stock 6,000 | $0.00 | 6,000 | direct |
ID | footnote |
---|---|
f1 | each restricted stock unit (rsu) represents a contingent right to receive one share of the issuer's common stock. |
f2 | the rsus, granted pursuant to the issuer's non-employee director compensation policy, vest in full on the earlier of (i) april 26, 2023 or (ii) the issuer's 2023 annual meeting of stockholders, subject to the reporting person's continued service on the board of directors. |